FORMOSA
LABORATORIES, INC.

Formosa Laboratories, Inc.

Disclaimer

This material has been prepared by Formosa Laboratories Inc. (“Formosalab”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. Formosalab is under no obligation to update or keep current the information contained herein. The information contained in this presentation is Formosalab’s confidential information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company as to, the accuracy or completeness of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of Formosalab. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future

events and future economic performances and projections of various financial items.

These forwardlooking statements involve known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from those implied by such forward-looking statements.

FORMOSA LABORATORIES, INC.

Company Profile

- Established Dec. 29, 1995
- SHO 120 M
- Headcount Total 809
- Business scope APIs (49 US DMFs, 15 EU DMFs, 14 JMFs)
  CRAM (Contract API RD & Manufacturing)
  DP Development
  UV Filters
- Inspected by TFDA, US FDA, Japan PMDA, German BGV, EDQM and Mexican COFEPRIS

FORMOSA LABORATORIES, INC.

Operation Results

FORMOSA LABORATORIES, INC.

2021 up to Nov. Top Line

NTD M	**2021**	**YoY**
Polymers	1,068	-4%
Vit. D Derivatives	560	6%
CDMO	124	4%
Others	1,069	9%
Total	**2,253**	**3%**

2017-2021 Income



FORMOSA LABORATORIES, INC.

Product Mixture



Profitability (unconsolidated)

2021Q1-3	
EPS	12.7元
BV per sh	62.4元



FORMOSA LABORATORIES, INC.

Business Update

Integrated Services



Global Quality System

Agency and country	Total inspection records	First time (year)	Last time (year)
US FDA	7	2004	2018
Germany BGV	2	2007	*
Japan PMDA	21	2009	2020
Mexico COFEPRIS	2	2010	*
Europe EDQM	1	2013	*
Taiwan TFDA	28	2002	2021

- GMP certificates on 42 products
- Granted with 49 US DMF, 15 EU DMF, 14 JMF and 8 COS

* Taiwan becomes a PIC/S member since 2013 and PIC/S members in principle will not need to inspect additionally

FORMOSA LABORATORIES, INC.

API products

- APIs Anticancers
- Anti-inflammatory &Analgesic Agents
- MRI Enhancing Agents
- Respiratory Agents
- Polymeric Drugs
- CNS Agents
- Immunomodulators
- Steroids
- Vit. D Derivatives
- Antibiotics

FORMOSA LABORATORIES, INC.

High Potent Facility



- Vit D derivatives
- Steroid hormones
- Anti-cancers
- ADCs

API Line Update

- ✓Sevelamer Carbonate / Sevelamer HCl
  - Exclusive for EU, strong demand
  - 45% US market share for the generics which occupied 99% of the total market
  - Expanded in the ROW
- ✓Colevelamer HCl
  - 100% of US generics market share except for the authorized generic player, generics had 97% of the total market, two additional clients added soon
  - Expected to see strong demand in EU in 2022
- ✓Colestipol
  - 100% of US generics market share except for the authorized generic player

API Line Update

● Vitamin D. Derivatives

Calciptriol: Strong demand from EU with +40% YoY in 2021

Alfacalcidol: Expected to get into Japan in 2022 with aim to have 70% market share

Calcifediol: Signed an exclusive supply agreement Oct. 2021, plan to have market share of 40% in 2024

● Cancer treatment (TMZ)

TMZ: Stable market demand in the US and expect to see new demand in the EU in 2022

● Leflunomide

Leflunomide: 70% market share in the US, Canada and EU

Mycophenolate Sodium: granted with US DMF

API Line Update

China

- ✓ Driven by BE and China/ US dual filing
- ✓ Benzonatate: commercialization in the US
- ✓ Sevelamer Carbonate: Expected to market in 2022
- ✓ Temozolomide/ Calcipotriol: Approved and marketed in 2021
- ✓ Alfacalcidol/ Montelukast/ Paricalcitol: Approved by NMDA
- ✓ Gadoterate Meglumine: Expected to market in 2022
- ✓ Mycophenolate Sodium: Clients filed in the US
- ✓ More than 10 products are in the process of registration in China

Strong CDMO Demand

- Provided services for domestic and international clients at all development stage from R to D and commercialization
- Well know ADC development service
- To see demand for drug product development

CDMO in spot



RD and Commercialization stage Income



- R&D process development → process validation
- pre-IND scale → commercial scale
- chemical sourcing → CMC documentation
- drug substance → drug product

ADC



- Payload linker
- Process Development
- Scale up
- Analysis
- Formulation development
- Drug Product Production

FORMOSA
LABORATORIES, INC.

Injection Plant

International Standard

- Designed by NNE
- USA(FDA), EU(EMA) and Japan (PMDA) standard
- Able to provide services for small molecule and protein drugs
- Capacity over 100M p.a., for regular line, cytotoxic line and pre-clinical stage clients
- In the process of facility inspection

Designed for all



FORMOSA LABORATORIES, INC.

Multiple Scale/ Score

Plant	Filling Line	INJ Type	Filling Quantity	Compounding Volume	Batch Size (vials)	Lyophilizer
V	V1 (Non-cytotoxic)	Vial	2mL~100mL	10L~1000L	10,000~250,000	30 m^2 x 2
		Lyophilized	2mL~100mL			
	V2 (Non-cytotoxic)	Vial	2mL~20mL	1L~60L	100~24,000	2.3 m^2
		Lyophilized	2mL~ 20mL			
		Pre-filled	0.5mL~3mL			N/A
D	D1 (Cytotoxic/ High Potent)	Vial	2mL~100mL	1L~100L	1,000~40,000	7.2 m^2
		Lyophilized	2mL~ 50mL			
		Pre-filled*	0.5mL~3mL			N/A

* Long term expansion plan

FORMOSA
LABORATORIES, INC.
台耀化學股份有限公司

Q&A